Thrombotic Microangiopathy Associated with Interferon Beta

被引：79

作者：

Hunt, David ^{[1
]}

Kavanagh, David ^{[2
]}

Drummond, Iain ^{[1
]}

Weller, Belinda ^{[1
]}

Bellamy, Chris ^{[1
]}

Overell, James ^{[3
]}

Evans, Stephen ^{[4
]}

Jackson, Andrew ^{[1
]}

Chandran, Siddharthan ^{[1
]}

机构：

[1] Univ Edinburgh, Edinburgh, Midlothian, Scotland

[2] Newcastle Univ, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England

[3] Univ Glasgow, Glasgow, Lanark, Scotland

[4] London Sch Hyg & Trop Med, London WC1, England

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 2014年 / 370卷 / 13期

基金：

英国医学研究理事会; 英国惠康基金;

关键词：

D O I：

10.1056/NEJMc1316118

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Recombinant interferon beta is commonly used in the treatment of multiple sclerosis. In this letter, cases of thrombotic microangiopathy that were reported in South Scotland appear to be related to the use of a particular preparation of interferon beta.To the Editor: Interferon beta is a widely prescribed recombinant-protein therapy with a well-established favorable safety profile.(1) Here, we describe an unexpectedly high number of cases of thrombotic microangiopathy associated with severe or malignant hypertension in four patients with multiple sclerosis who were receiving therapy with recombinant interferon beta in South Scotland. A detailed review of the case histories of these patients, including a genetic analysis, did not identify any other causal factor for this condition, and an analysis of pharmacy records revealed a significant association with a common manufacturing source of interferon beta (Rebif, Merck) (Figure 1, and the ...

引用

页码：1270 / 1271

页数：2

共 4 条

[1]

[Anonymous], 2013, DRUG SAFETY UPDATE, pS3

[2] Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis [J].

Ebers, GC ;

Rice, G ;

Lesaux, J ;

Paty, D ;

Oger, J ;

Li, DKB ;

Beall, S ;

Devonshire, V ;

Hashimoto, S ;

Hooge, J ;

Kastrukoff, L ;

Krieger, C ;

Mezei, M ;

Seland, P ;

Vorobeychi, G ;

Morrison, W ;

Nelson, J ;

Freedman, MS ;

Chrisie, S ;

Nelson, R ;

Rabinovitch, H ;

Freedman, C ;

Hartung, HP ;

Rieckmann, P ;

Archelos, J ;

Jung, S ;

Weilbach, F ;

Flachenecke, P ;

Sauer, J ;

Hommes, O ;

Jongen, P ;

Brouwer, S ;

McLeod, J ;

Pollard, J ;

Ng, R ;

Sandberg-Wollheim, M ;

Källén, K ;

Nilsson, P ;

Ekberg, R ;

Lundgren, A ;

Jadbäck, G ;

Wikström, J ;

Multanen, J ;

Valjakka, M ;

Carton, H ;

Lissoir, F ;

Declerq, I ;

Vieren, M ;

Peeters, E ;

Dubois, B .

LANCET, 1998, 352 (9139) :1498-1504

[3]

Ebers GC, 1999, LANCET, V353, P678

[4] Safety and immunogenicity of a new formulation of interferon β-1a (Rebif® New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results [J].

Giovannoni, G. ;

Barbarash, O. ;

Casset-Semanaz, F. ;

King, J. ;

Metz, L. ;

Pardo, G. ;

Simsarian, J. ;

Sorensen, P. S. ;

Stubinski, B. .

MULTIPLE SCLEROSIS JOURNAL, 2009, 15 (02) :219-228

← 1 →